News and Trends 21 Jun 2022
New data demonstrates clinical potential of Inivata’s RaDaR technology for breast cancer
Data supporting the detection of minimal residual disease (MRD) has highlighted potential to provide an early predictor of tumor recurrence in patients who have had breast cancer. Liquid biopsy company Inivata announced the new data in support of its new RaDaR assay for the detection of MRD in those with high-risk hormone receptor-positive (HR+), human […]